The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | The advantages of allogeneic products derived from healthy donors
LaQuisa Hill, MD, Texas Children’s Hospital, Houston Methodist Hospital, Houston, TX, describes the role of allogeneic products in treating B-cell and T-cell lymphomas. Using healthy donor cells to manufacture allogeneic therapies can increase overall quality and expedite treatment in patients. Despite graft versus host disease (GvHD) being a concern, such cases have not been seen in patients. Dr Hill additionally highlights the development of anti-CD37 allogeneic products. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
